Factors impeding the discovery of an intervention-based treatment for type 1 diabetes

Clinical and Experimental Immunology

Volumn 183, Issue 1, 2016, Pages 1-7

  von Herrath, M G ^a,b   Korsgren, O ^c   Atkinson, M A ^d  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b NOVO NORDISK INC   (United States)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

Autoimmune disease; Beta cells; Immune therapy; Insulin; Type 1 diabetes

Indexed keywords

ANTIGEN; AUTOANTIBODY; BIOLOGICAL MARKER; C PEPTIDE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; INSULIN;

AGE; ARTICLE; AUTOIMMUNITY; CLINICAL RESEARCH; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); COMMUNITY; DISEASE COURSE; DRUG SAFETY; EXOCRINE SECRETION; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INTERVENTION STUDY; PANCREAS; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PATHOGENESIS; PATIENT CARE; PRIORITY JOURNAL; T LYMPHOCYTE; ADULT; ANIMAL; CHILD; DIABETES MELLITUS, TYPE 1; GLUCOSE BLOOD LEVEL; METABOLISM; PATHOLOGY; TRANSLATIONAL RESEARCH;

ADULT; ANIMALS; BLOOD GLUCOSE; CHILD; DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PANCREAS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84955353427     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12656     Document Type: Article

References (31)

1. Skyler JS. Update on worldwide efforts to prevent type 1 diabetes. Ann NY Acad Sci 2008; 1150:190-6.
2. Herold KC, Hagopian W, Auger JA et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346:1692-8.
3. Keymeulen B, Vandemeulebroucke E, Ziegler AG et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352:2598-608.
4. Keymeulen B, Walter M, Mathieu C et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010; 53:614-23.
5. Bach JF. Anti-CD3 antibodies for type 1 diabetes: beyond expectations. Lancet 2011; 378:459-60.
6. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009; 361:2143-52.
7. Dantal J, Soulillou JP. Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med 2005; 352:1371-3.
8. Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology 2015; 61:703-11.
9. Battaglia M, Atkinson MA. The streetlight effect in type 1 diabetes. Diabetes 2015; 64:1081-90.
10. Todd JA, Wicker LS. Genetic protection from the inflammatory disease type 1 diabetes in humans and animal models. Immunity 2001; 15:387-95.
11. Atkinson MA. Losing a grip on the notion of beta-cell specificity for immune responses in type 1 diabetes: can we handle the truth? Diabetes 2014; 63:3572-4.
12. Eisenbarth GS. Banting lecture 2009: an unfinished journey: molecular pathogenesis to prevention of type 1A diabetes. Diabetes 2010; 59:759-74.
13. In't VP. Insulitis in human type 1 diabetes: the quest for an elusive lesion. Islets 2011; 3:131-8.
14. Eisenbarth GS. Insulin autoimmunity: immunogenetics/immunopathogenesis of type 1A diabetes. Ann NY Acad Sci 2003; 1005:109-18.
15. Krogvold L, Skog O, Sundstrom G et al. Function of isolated pancreatic islets from patients at onset of type 1 diabetes; Insulin secretion can be restored after some days in a non-diabetogenic environment in vitro. Results from the DiViD study. Diabetes 2015; 64:2506-12.
16. Rodriguez-Calvo T, Ekwall O, Amirian N, Zapardiel-Gonzalo J, von Herrath MG. Increased immune cell infiltration of the exocrine pancreas: a possible contribution to the pathogenesis of type 1 diabetes. Diabetes 2014; 63:3880-90.
17. Gaglia JL, Guimaraes AR, Harisinghani M et al. Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients. J Clin Invest 2011; 121:442-5.
18. Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 1965; 14:619-33.
19. Arif S, Leete P, Nguyen V et al. Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes. Diabetes 2014; 63:3835-45.
20. Foulis AK, Farquharson MA, Hardman R. Aberrant expression of class II major histocompatibility complex molecules by B cells and hyperexpression of class I major histocompatibility complex molecules by insulin containing islets in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1987; 30:333-43.
21. Bottazzo GF, Dean BM, McNally JM, MacKay EH, Swift PG, Gamble DR. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med 1985; 313:353-60.
22. Skog O, Korsgren S, Wiberg A et al. Expression of human leukocyte antigen class I in endocrine and exocrine pancreatic tissue at onset of type 1 diabetes. Am J Pathol 2015; 185:1129-138.
23. Pugliese A, Yang M, Kusmarteva I et al. The juvenile diabetes research foundation network for pancreatic organ donors with diabetes (nPOD) program: goals, operational model and emerging findings. Pediatr Diabetes 2014; 15:1-9.
24. Haller MJ, Gitelman SE, Gottlieb PA et al. Anti-thymocyte globulin/G-CSF treatment preserves beta cell function in patients with established type 1 diabetes. J Clin Invest 2015; 125:448-55.
25. Greenbaum CJ, Beam CA, Boulware D et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 2012; 61:2066-73.
26. Lachin JM, McGee P, Palmer JP. Impact of C-peptide preservation on metabolic and clinical outcomes in the diabetes control and complications trial. Diabetes 2014; 63:739-48.
27. Hagopian W, Ferry RJ Jr, Sherry N et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protege trial. Diabetes 2013; 62:3901-8.
28. Trudeau JD, Kelly-Smith C, Verchere CB et al. Prediction of spontaneous autoimmune diabetes in NOD mice by quantification of autoreactive T cells in peripheral blood. J Clin Invest 2003; 111:217-23.
29. Skyler JS. Immune therapy for treating type 1 diabetes: challenging existing paradigms. J Clin Invest 2015; 125:94-6.
30. von HM. Combination therapies for type 1 diabetes: why not now? Immunotherapy 2010; 2:289-91.
31. Rigby MR, DiMeglio LA, Rendell MS et al. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol 2013; 1:284-94.